Filing Analysis
This is an amendment to a previous 8-K filing regarding the results of the company's 2024 Annual Meeting of Shareholders. The primary purpose is to disclose that shareholders voted in favor of conducting 'Say-on-Pay' advisory votes on an annual basis.
📋 Key Facts
- The filing is an Amendment (8-K/A) to the original report filed on August 30, 2024.
- Shareholders at the August 29, 2024 Annual Meeting voted in favor of conducting advisory Say-on-Pay votes annually.
- The Board of Directors will conduct these votes every year until a new vote regarding frequency is held.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures in the attached exhibit.
📋 Key Facts
- Reporting date: November 7, 2024
- Period covered: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- Signed by Brian Brown, Chief Financial Officer.
Co-Diagnostics, Inc. held its 2024 annual meeting of shareholders on August 29, 2024. The filing reports the results of shareholder votes regarding director elections, executive compensation advisory votes, and the ratification of the independent auditor.
📋 Key Facts
- James Nelson was elected to a three-year term as a director with 6,684,070 votes in favor.
- Shareholders approved the non-binding resolution on executive officer compensation (Say-on-Pay) with 9,312,471 votes for and 1,279,949 against.
- Shareholders voted to maintain an annual frequency (One Year) for future advisory votes on executive compensation.
- The appointment of Tanner LLC as the independent registered public accounting firm for the year ending December 31, 2024, was ratified with 13,285,933 votes in favor.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- The filing includes information regarding the use of non-GAAP financial measures.
Co-Diagnostics, Inc. announced the submission of a 510(k) application to the FDA for its Co-Dx™ PCR Pro™ Platform on June 14, 2024.
📋 Key Facts
- Company submitted a 510(k) Application to the FDA.
- The application is specifically for the Co-Dx™ PCR Pro™ Platform.
- Filing date: June 14, 2024.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a formal announcement of earnings and includes non-GAAP financial measures in the attached press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 9, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Co-Diagnostics, Inc. announced the appointment of Richard Abbott as President on March 15, 2024. Mr. Abbott previously served as President of Advanced Conceptions, Inc., a subsidiary acquired by the company in December 2021.
🚩 Red Flags
- Related-party transaction potential: Abbott's entity (Whiteknob LLC) has ongoing milestone-based equity incentives tied to the prior acquisition.
📋 Key Facts
- Richard Abbott appointed as President effective March 15, 2024.
- Abbott was previously President of Advanced Conceptions, Inc. (a wholly owned subsidiary) from January 2021 to March 2024.
- Advanced Conceptions was acquired by Co-Diagnostics in December 2021.
- Whiteknob LLC (owned 50% by Abbott) held a 71.61% interest in Advanced Conceptions at the time of acquisition.
- Contingent consideration: Whiteknob LLC may earn an additional 507,386 common shares and 166,503 warrants upon achievement of milestones.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of earnings and includes non-GAAP financial measures in the attached press release.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and non-GAAP measures
- Signed by Brian Brown, Chief Financial Officer